Recent Updates
Recently added Catalysts
RCUS Positive Sentiment

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Tuesday, September 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcus Biosciences is set to host an investor event on October 20, 2026, in New York City. The event will feature new data from the ARC-20 platform study, which evaluates casdatifan as a treatment for kidney cancer across multiple lines of therapy. This highlights the company's commitment to advancing cancer treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arcus Biosciences is showcasing promising new data.
  • The event will focus on casdatifan for kidney cancer treatment.
  • The company is actively engaging with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
2.8%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Etrumadenant
Phase 1 · Non-small Cell Lung Cancer

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City. The event will highlight new data from the ARC-20 platform study, which is evaluating casdatif

Frequently Asked Questions

When is the Arcus Biosciences investor event?

The investor event is scheduled for October 20, 2026.

What will be discussed at the investor event?

The event will highlight new data from the ARC-20 platform study.

Where will the investor event take place?

The event will be held in New York City.

What is casdatifan used for?

Casdatifan is being evaluated as a treatment for kidney cancer.

ShareAdd on Google
Tags: RCUS Viatris Investor Conferences Healthcare Arcus Biosciences casdatifan kidney cancer investor event ARC-20 platform
Last updated: Sep 22, 2026

Biotech snapshot

Cash runway
$775M liquidity · $40M/mo burn
~18 mo
Low dilution risk
Lead asset
EtrumadenantPhase 1
Non-small Cell Lung Cancer →

Catalyst track record

+65%
best trade around RCUS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for RCUS.

See every catalyst's timing & PoA →